9 Stocks To Buy For Long Term: Goldman Sachs picks stocks for 2026 with up to 112% upside; HUL, Max Healthcare, Info Edge on list

Info Edge India is rated Buy, with the stock trading at Rs 1,124.20 and a revised target price of Rs 1,530, implying an upside of around 36.1 per cent. Goldman Sachs maintained its positive view while cutting the target from Rs 1,700, reflecting valuation adjustments.

Cohance Lifesciences carries a Buy rating, trading at Rs 306 with a target price of Rs 650, indicating an upside of about 112.4 per cent. Goldman Sachs remains constructive despite lowering the target from Rs 750, citing long-term growth potential.

Hindustan Unilever is rated Buy, with the stock trading at Rs 2,318.30 and a target price of Rs 2,750, translating into an upside of around 18.6 per cent. Goldman Sachs expects gradual recovery ahead, supported by strategic initiatives, improving foods performance and accelerating home care growth.

Mahindra & Mahindra carries a Buy rating, trading at Rs 3,506.30 with a target price of Rs 4,400, suggesting an upside of about 25.5 per cent. Goldman Sachs raised the target from Rs 4,300, reflecting continued strength in core segments.

Eicher Motors is rated Buy, with the stock trading at Rs 8,000.50 and a revised target price of Rs 8,600, implying an upside of around 7.5 per cent. Goldman Sachs raised its target slightly, backed by steady long-term demand outlook.

Neuland Laboratories has a Buy rating, trading at Rs 13,296 with a target price of Rs 17,325, indicating an upside of about 30.3 per cent. Goldman Sachs expects topline acceleration driven by Unit III monetisation, ramp-up in niche molecules and stronger CMS mix.

Krishna Institute of Medical Sciences is rated Buy, with the stock trading at Rs 681.35 and a target price of Rs 875, implying an upside of around 28.4 per cent. Goldman Sachs maintained its positive stance despite trimming the target from Rs 900.

Crompton carries a Buy rating, trading at Rs 274.25 with a target price of Rs 340, translating into an upside of about 24.0 per cent. Goldman Sachs raised its target from Rs 330, citing improving outlook in the consumer electrical space.

Max Healthcare is rated Buy, with the stock trading at Rs 1,075 and a target price of Rs 1,300, implying an upside of around 20.9 per cent. Goldman Sachs maintained its Buy call while slightly cutting the target from Rs 1,325.

The views/suggestions/recommendations expressed in this article are solely those of investment experts. The platform does not advise investors to buy or sell stocks. Please consult your financial adviser before making investment decisions.